Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 19, 2024 08:00 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a biopharmaceutical company focused on developing and advancing...
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
August 15, 2024 07:30 ET
|
ABVC BioPharma, Inc.
• Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings •...
Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024 08:05 ET
|
Palisade Bio, Inc.
– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Company continues to...
COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results
August 13, 2024 08:05 ET
|
COSCIENS Biopharma Inc.
Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024 Company ended the quarter with US$27.8...
Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis
August 08, 2024 08:00 ET
|
Palisade Bio, Inc.
– Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before year end – Based on the modeling and simulations, Palisade has established dose...
Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain
August 01, 2024 06:00 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Palisade Bio Participates in Virtual Investor “What this Means” Segment
July 31, 2024 09:15 ET
|
Palisade Bio, Inc.
Mitch Jones, MD, PhD, CMO of Palisade Bio highlights recent findings from a microbiome study confirming local bioactivation of lead product candidate, PALI-2108 Carlsbad, CA, July 31, 2024 ...
Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108
July 29, 2024 08:30 ET
|
Palisade Bio, Inc.
Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis (UC) patients Company advancing toward commencement of...
Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement
July 22, 2024 08:00 ET
|
Hepion Pharmaceuticals, Inc.
Pharma Two B Ltd. (“Pharma Two B”) has entered into a merger agreement with Hepion Pharmaceuticals, Inc. (“Hepion”) (Nasdaq: HEPA)Immediately upon completion of the merger, current Pharma Two B...
Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108
July 19, 2024 08:30 ET
|
Palisade Bio, Inc.
Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar...